Drug intelligence / Profile preview

OA02 peptide

Development stage: Preclinical
Lead developer: University of California, Davis
Modality: Nanoparticles → Drug Delivery Systems, Peptides
Administration: Intravenous

Overview

The OA02 peptide is a high-affinity peptide designed to specifically target the alpha-3 integrin receptor, which is overexpressed on the surface of ovarian cancer cells. It is utilized as a targeting moiety to facilitate the precise delivery of chemotherapeutic drugs, such as paclitaxel, encapsulated within micellar nanoparticles. This targeted approach aims to enhance the antitumor efficacy of the drug while simultaneously reducing systemic toxicity by concentrating the therapeutic agent at the tumor site. The peptide's conjugation to nanoparticles allows for receptor-mediated endocytosis, leading to increased uptake by cancer cells.

Other names: high-affinity OA02 peptide

Targets

α3β1 (Integrin alpha 3 beta 1)

Beyond the preview

Go deeper on OA02 peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OA02 peptide.

Explore the full profile